Business Wire

GA-IDEMIA

10.2.2021 14:02:11 CET | Business Wire | Press release

Share
Honeywell and IDEMIA Announce Strategic Alliance to Develop Intelligent Building Offering

Honeywell (NYSE: HON) , a global leader in connected buildings, and IDEMIA, the global leader in Augmented Identity, today announced a strategic alliance to create and cultivate an intelligent building ecosystem that provides a more seamless and enhanced experience for operators and occupants alike. The alliance will integrate Honeywell’s security and building management systems with IDEMIA’s biometric-based access control systems to create frictionless, safer and more efficient buildings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005454/en/

The Honeywell and IDEMIA alliance is intended to design solutions that will allow occupants to easily and securely have contactless engagement with a building – from vehicle recognition at the car park and automatic elevator calls to biometric-based access and personalized conference room settings. With a focus on security and data privacy, these next-generation solutions will provide occupants with a safer, more efficient and more enjoyable experience that will help building owners attract tenants.

“We recognize that our customers need to deliver business outcomes like managing complex security requirements and providing healthier, more productive environments,” said Manish Sharma, vice president, chief technology and chief product officer for Honeywell Building Technologies. “By working with IDEMIA we will create an intelligent building ecosystem that better addresses our customers’ key challenges and drives their desired outcomes. Whether it’s a commercial office building, a hospital or an airport, we have the ability to change the way people experience and interact with buildings for the better.”

“We look forward to expanding our long-standing relationship with Honeywell to bring greater value to our customers with more integrated solutions that make for a more seamless building experience,” said Matt Cole, CEO, Secure Enterprise Transactions Division, IDEMIA. “The ability for our technology to easily integrate with Honeywell safety and security systems will provide building owners and operators more insight and control into creating more efficient buildings, while putting the occupant experience first.”

IDEMIA’s field-proven AI-based products and solutions -- like MorphoWave TM , a contactless fingerprint device that scans four fingerprints in less than one second; VisionPass, the most advanced facial recognition terminal; or Augmented Vision, a biometric video analytics platform -- integrate with Honeywell security and building management systems. Honeywell’s systems include Pro-Watch Integrated Security Suite, MAXPRO Cloud and Enterprise Buildings Integrator.

Honeywell and IDEMIA will work together to deliver more powerful integrations through aligned product creation and joint product roadmaps. The integrated offerings will allow building operators to respond rapidly and effectively to alarms or incidents by providing an incident workflow package that allows Standard Operating Procedures (SOPs) to be configured, reducing compliance exceptions, security risks and response times.

IDEMIA products also support Honeywell’s Healthy Buildings solutions that help building owners improve building environments, operate more cleanly and safely and encourage sustained compliance with changing building standards, safety guidelines, government-issued regulations and a company's risk management policies. Honeywell's Healthy Buildings solutions provide a holistic view of a building's health based on key factors such as indoor air quality, occupant flow, personal protection equipment (PPE) analytics, contactless access, thermal screening, social distancing and sanitation efficacy.

To learn more about Honeywell and IDEMIA collaborations click here .

# # #

About IDEMIA

IDEMIA, the global leader in augmented identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for augmented identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide augmented identity for international clients from financial, telecom, identity, public security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter.

About Honeywell Building Technologies

Honeywell Building Technologies (HBT) is a global business with more than 18,000 employees. HBT creates products, software and technologies found in more than 10 million buildings worldwide. Commercial building owners and operators use our technologies to help create safe, energy efficient, sustainable and productive facilities. For more news and information on Honeywell Building Technologies, visit http://www.honeywell.com/newsroom .

Honeywell (www.honeywell.com ) is a Fortune 100 technology company that delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye